vTv Therapeutics (VTVT) EPS (Weighted Average and Diluted) (2020 - 2025)
Historic EPS (Weighted Average and Diluted) for vTv Therapeutics (VTVT) over the last 6 years, with Q3 2025 value amounting to -$1.08.
- vTv Therapeutics' EPS (Weighted Average and Diluted) fell 2272.73% to -$1.08 in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.27, marking a year-over-year increase of 2781.46%. This contributed to the annual value of -$3.2 for FY2024, which is 6705.39% up from last year.
- Per vTv Therapeutics' latest filing, its EPS (Weighted Average and Diluted) stood at -$1.08 for Q3 2025, which was down 2272.73% from -$0.92 recorded in Q2 2025.
- In the past 5 years, vTv Therapeutics' EPS (Weighted Average and Diluted) registered a high of -$0.01 during Q2 2021, and its lowest value of -$9.78 during Q4 2022.
- Moreover, its 5-year median value for EPS (Weighted Average and Diluted) was -$0.9 (2024), whereas its average is -$1.9.
- In the last 5 years, vTv Therapeutics' EPS (Weighted Average and Diluted) plummeted by 2412361.79% in 2021 and then skyrocketed by 8292.43% in 2023.
- Over the past 5 years, vTv Therapeutics' EPS (Weighted Average and Diluted) (Quarter) stood at -$8.19 in 2021, then fell by 19.41% to -$9.78 in 2022, then soared by 82.92% to -$1.67 in 2023, then surged by 62.29% to -$0.63 in 2024, then plummeted by 71.51% to -$1.08 in 2025.
- Its EPS (Weighted Average and Diluted) stands at -$1.08 for Q3 2025, versus -$0.92 for Q2 2025 and -$0.77 for Q1 2025.